Sintx Technologies (NASDAQ:SINT) and LENSAR (NASDAQ:LNSR) Critical Analysis

Sintx Technologies (NASDAQ:SINT) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sintx Technologies and LENSAR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	3	0	2.50
LENSAR	1	0	2	0	2.33

Sintx Technologies currently has a consensus target price of $9.50, indicating a potential upside of 508.97%. LENSAR has a consensus target price of $11.33, indicating a potential upside of 107.95%. Given Sintx Technologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe Sintx Technologies is more favorable than LENSAR.

Valuation & Earnings

This table compares Sintx Technologies and LENSAR”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02 million	6.61	-$10.36 million	($4.91)	-0.32
LENSAR	$58.44 million	1.15	-$34.28 million	($0.33)	-16.52

Sintx Technologies has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 40.1% of LENSAR shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by insiders. Comparatively, 65.8% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sintx Technologies and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-281.91%	-323.34%	-100.95%
LENSAR	57.57%	-529.08%	50.03%

Summary

Sintx Technologies beats LENSAR on 7 of the 13 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.